References
- Alberta Health Services. Multiple Myeloma Clinical Practice Guideline. 2015.
- Nooka AK, Kastritis E, Dimopoulos MA, et al. Treatment options for relapsed and refractory multiple myeloma. Blood. 2015; 125(20):3085–3099.
- Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020; 20(1):1087.
- Parikh K, Purnomo L, Abouzaid S, et al. Real world treatment patterns, time to next treatment and economic outcomes in relapsed multiple myeloma patients treated with pomalidomide or carfilzomib. 2016 ASCO Annual Meeting; June 6, 2016.
- Parikh K, Ni Q, Zafar F, et al. Health and Economic Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with RVd Versus CyBord: A U.S. Claims-Based Analysis. AMCP Managed Care & Specialty Pharmacy Annual Meeting 2017; March 27–30, 2017; Denver, Colorado: Journal of Managed Care & Specialty Pharmacy; 2017. p. S33.
- Lee C, Grigorian M, Nolan R, et al. A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma. J Med Econ. 2016;19(4):397–402.
- Chen CC, Parikh K, Abouzaid S, et al. Real-World treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or carfilzomib. J Manag Care Spec Pharm. 2017; 23(2):236–246.
- Sharkey M, McKavanagh D, Walpole E, et al. Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting. Int J Clin Pharm. 2017;39(4):836–843.
- Kotchetkov R, Masih-Khan E, Chu CM, et al. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients. Cancer Med. 2017;6(1):3–11.
- Palmaro A, Gauthier M, Conte C, et al. Identifying multiple myeloma patients using data from the french health insurance databases: Validation using a cancer registry. Medicine. 2017;96(12):e6189.
- Princic N, Gregory C, Willson T, et al. Development and validation of an algorithm to identify patients with multiple myeloma using administrative claims data. Front Oncol. 2016;6:224.
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.
- Halfon P, Eggli Y, van Melle G, et al. Measuring potentially avoidable hospital readmissions. J Clin Epidemiol. 2002;55(6):573–587.
- Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
- Song X, Cong Z, Wilson K. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr Med Res Opin. 2016;32(1):95–103.
- Davies F, Rifkin R, Costello C, et al. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Ann Hematol. 2021;100(9):2325–2337.
- National Cancer Institute. Cancer Stat Facts: Myeloma 2021. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html.
- Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175(2):252–264.
- MacEwan JP, Batt K, Yin W, et al. Economic burden of multiple myeloma among patients in successive lines of therapy in the United States. Leuk Lymphoma. 2018;59(4):941–949.
- Areethamsirikul N, Masih-Khan E, Chu CM, et al. CyBorD induction therapy in clinical practice. Bone Marrow Transplant. 2015;50(3):375–379.